170 related articles for article (PubMed ID: 37541303)
21. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
22. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
23. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
24. Dual regulation of SIRPalpha phosphorylation by integrins and CD47.
Johansen ML; Brown EJ
J Biol Chem; 2007 Aug; 282(33):24219-30. PubMed ID: 17584740
[TBL] [Abstract][Full Text] [Related]
25. CD47-mediated immune evasion in early-stage lung cancer progression.
Chuang CH; Zhen YY; Ma JY; Lee TH; Hung HY; Wu CC; Wang PH; Huang CT; Huang MS; Hsiao M; Lee YR; Huang CF; Chang YC; Yang CJ
Biochem Biophys Res Commun; 2024 Aug; 720():150066. PubMed ID: 38749193
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
Front Immunol; 2020; 11():593219. PubMed ID: 33329583
[TBL] [Abstract][Full Text] [Related]
27. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.
Biscardi JS; Maa MC; Tice DA; Cox ME; Leu TH; Parsons SJ
J Biol Chem; 1999 Mar; 274(12):8335-43. PubMed ID: 10075741
[TBL] [Abstract][Full Text] [Related]
28. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
29. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
30. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
[TBL] [Abstract][Full Text] [Related]
31. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
[TBL] [Abstract][Full Text] [Related]
32. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Asbagh LA; Vazquez I; Vecchione L; Budinska E; De Vriendt V; Baietti MF; Steklov M; Jacobs B; Hoe N; Singh S; Imjeti NS; Zimmermann P; Sablina A; Tejpar S
Oncotarget; 2014 Oct; 5(20):10070-83. PubMed ID: 25301722
[TBL] [Abstract][Full Text] [Related]
33. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
[TBL] [Abstract][Full Text] [Related]
34. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
Hu LY; Zhuang WT; Chen MJ; Liao J; Wu DF; Zhang YX; Pang LL; Huang YH; Mao TQ; Yang MJ; Peng PJ; Liang JX; Chen L; Zeng LJ; Zhang L; Fang WF
J Thorac Oncol; 2024 Mar; ():. PubMed ID: 38553005
[TBL] [Abstract][Full Text] [Related]
35. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
36. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
37. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.
Wang Z; Li B; Li S; Lin W; Wang Z; Wang S; Chen W; Shi W; Chen T; Zhou H; Yinwang E; Zhang W; Mou H; Chai X; Zhang J; Lu Z; Ye Z
Nat Commun; 2022 Oct; 13(1):6308. PubMed ID: 36274066
[TBL] [Abstract][Full Text] [Related]
38. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
39. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
